Scientific Presentations at Society Meetings

European Atherosclerosis Society
Mason R, Sherratt S. Eicosapentaenoic Acid (EPA) Inhibits Human Low-Density Lipoprotein Oxidation in a Concentration- And Time-Dependent Manner at Pharmacologic Doses In Vitro [abstract EAS19-0568]. Atherosclerosis. 2019; in press.

https://www.atherosclerosis-journal.com/article/S0021-9150(19)30687-2/fulltext

Academy of Managed Care Pharmacy

Hilleman D, Teply R, Packard K. Knowledge, perceptions, and patterns of fish oil use in cardiac patients [abstract I16]. J Manag Care Spec Pharm. 2018;24(4 suppl a):S71. https://www.jmcp.org/doi/pdf/10.18553/jmcp.2018.24.4-a.s1

American College of Cardiology

Bhatt DL, Steg G, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif J-C, Gregson J, Pocock SJ, Ballantyne CM, on behalf of the REDUCE-IT Investigators. Reduction in total ischemic events in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. Presented at the annual meeting of the American College of Cardiology, March 16-18, 2019, New Orleans, Louisiana.

Toth P, Granowitz C, Hull M, Philip S. Long-term statin persistence is poor among high-risk patients with baseline peripheral artery disease: a real-world administrative claims analysis of the Optum research database [abstract]. J Am Coll Cardiol. 2019;73:1744.

http://www.onlinejacc.org/content/73/9_Supplement_1/1744

Wong ND, Fan W, Philip S, Granowitz C, Toth P. Burden of atherosclerotic cardiovascular disease risk in persons with elevated triglyceride levels according to statin use [abstract]. J Am Coll Cardiol. 2019;73:1763. 

http://www.onlinejacc.org/content/73/9_Supplement_1/1763

Leatherman S, Ferguson R, Weir I, et al. Increased residual cardiovascular risk in US veterans and moderately-elevated baseline triglycerides and well-controlled LCL-C levels on statins [abstract]. J Am Coll Cardiol. 2019;73:1719. http://www.onlinejacc.org/content/73/9_Supplement_1/1719

Navar AM, Pagidipati N, Mulder H, et al. Triglycerides as a risk factor for coronary heart disease: what measure and what cutoff? [abstract]. J Am Coll Cardiol. 2019;73. http://www.onlinejacc.org/content/73/9_Supplement_1/1865 

Mason RP, Sherratt SCR. Eicosapentaenoic acid inhibits membrane lipid oxidation in a concentration-dependent manner at pharmacologic doses in vitro [abstract]. J Am Coll Cardiol. 2019;73:2075. http://www.onlinejacc.org/content/73/9_Supplement_1/2075

Toth P, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. Long-term renal function worsens in high cardiovascular risk patients with high triglycerides and well-controlled low-density lipoprotein cholesterol in a real-world analysis [abstract]. J Am Coll Cardiol. 2018;71(11 suppl):A1445.

http://www.onlinejacc.org/content/71/11_Supplement/A1445

Miller M, Ballantyne C, Bays H, Granowitz C, Doyle R, Juliano R, Philip S. Icosapent ethyl (eicosapentaenoic acid ethyl ester) reduces potentially atherogenic lipid, lipoprotein, apolipoprotein, and inflammatory parameters in high-risk, statin-treated patients with persistent elevated triglycerides and high-sensitivity C-reactive protein: a post hoc subanalysis of the ANCHOR study [abstract]. J Am Coll Cardiol. 2018;71(11 suppl):A1392. http://www.onlinejacc.org/content/71/11_Supplement/A1392